Achilles therapeutics presents data at the 2021 european society for gene and cell therapy (esgct) congress demonstrating its proprietary manufacturing process can generate potent, personalized anti-cancer cell therapy candidates in multiple solid tumor types

London, oct. 22, 2021 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing precision t cell therapies to treat solid tumors, today delivered an oral presentation (or54) at the 2021 european society for gene and cell therapy (esgct) congress. in the presentation entitled ‘multicentre, prospective research protocol for development of a clonal neoantigen-reactive t cell (cnet) therapy pipeline across multiple tumour types,' dr. michael grant, associate medical director at achilles, reviewed initial data from the company's material acquisition platform (map)​ showing that achilles' proprietary velos™ manufacturing process is able to extract tumor infiltrating lymphocytes (til) and generate potent clonal neoantigen-reactive t cells (cnet) across a range of solid tumor types. cnet target clonal neoantigens, which are unique proteins expressed on every cancer cell within a patient but not on healthy tissue.
ACHL Ratings Summary
ACHL Quant Ranking